Langerhans cell histiocytosis · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cladribine and Cytarabine Variant #01 | — | R 87 084 | 21d | — | — | ~3 | ~R 261 251 indirect | — |
Cladribine monotherapy Variant #03 | — | R 34 921 | 35d | — | — | ~1 | ~R 34 921 indirect | — |
Cobimetinib monotherapy Variant #01 | — | R 28 004 | 28d | — | — | ~2 | ~R 56 008 indirect | — |
Vemurafenib monotherapy Variant #01 | — | R 13 464 | 28d | ~7.2 mo | ~15.5 mo | ~2 | ~R 26 928 PFS proxy · indirect | 4 |
4 of 4 regimens shown